Search Results - "Ticagrelor/adverse effects"

Coronary no-reflow and adverse events in patients with acute myocardial infarction after percutaneous coronary intervention with current drug-eluting stents and third-generation P2Y12 inhibitors

Authors: Gjin Ndrepepa Salvatore Cassese Erion Xhepa et al.

Source: Clin Res Cardiol
Clinical research in cardiology, 113(7):1006-1016

Subject Terms: Male, Ticagrelor, Time Factors, Myocardial Infarction, Percutaneous Coronary Intervention/methods [MeSH], Purinergic P2Y Receptor Antagonists/administration, Aged [MeSH], No-Reflow Phenomenon/epidemiology [MeSH], Prasugrel Hydrochloride/adverse effects [MeSH], Prasugrel Hydrochloride/administration, Risk Factors [MeSH], Platelet Aggregation Inhibitors/therapeutic use [MeSH], Prognosis, Acute myocardial infarction, No-Reflow Phenomenon/etiology [MeSH], Platelet Aggregation Inhibitors/administration, Male [MeSH], Ticagrelor/therapeutic use [MeSH], Drug-Eluting Stents [MeSH], Purinergic P2Y Receptor Antagonists/therapeutic use [MeSH], Coronary no-reflow, Purinergic P2Y Receptor Antagonists/adverse effects [MeSH], Female [MeSH], Follow-Up Studies [MeSH], Prasugrel Hydrochloride/therapeutic use [MeSH], Humans [MeSH], Ticagrelor/administration, Treatment Outcome [MeSH], Ticagrelor/adverse effects [MeSH], Incidence [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Time Factors [MeSH], Percutaneous Coronary Intervention/adverse effects [MeSH], Myocardial Infarction/epidemiology [MeSH], Original Paper, Platelet Aggregation Inhibitors/adverse effects [MeSH], Percutaneous coronary intervention, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, Risk Factors, Humans, Aged, Retrospective Studies, Incidence, Drug-Eluting Stents, Middle Aged, Medical and Health Sciences, ddc, 3. Good health, Treatment Outcome, Purinergic P2Y Receptor Antagonists, No-Reflow Phenomenon, Female, Prasugrel Hydrochloride, Platelet Aggregation Inhibitors, Follow-Up Studies

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/37962571
https://repository.publisso.de/resource/frl:6522589
https://mediatum.ub.tum.de/doc/1763441/document.pdf

Bleeding risk and P2Y12 inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: a single-centre cohort study: a single-centre cohort study

Authors: Mia Ravn Jacobsen Reza Jabbari Thomas Engstrøm et al.

Source: Jacobsen, M R, Jabbari, R, Engstrøm, T, Grove, E L, Glinge, C, Pedersen, F, Holmvang, L, Køber, L, Torp-Pedersen, C, Maeng, M, Veien, K, Freeman, P, Charlot, M G, Kelbæk, H & Sørensen, R 2023, 'Bleeding risk and P2Y12-inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: a single-centre cohort study', European Heart Journal-Cardiovascular Pharmacotherapy, vol. 9, no. 7, pvad048, pp. 617-626. https://doi.org/10.1093/ehjcvp/pvad048
Jacobsen, M R, Jabbari, R, Engstrøm, T, Grove, E L, Glinge, C, Pedersen, F, Holmvang, L, Køber, L, Torp-Pedersen, C, Maeng, M, Veien, K, Freeman, P, Charlot, M G, Kelbæk, H & Sørensen, R 2023, 'Bleeding risk and P2Y12-inhibitors in all-comer patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention : a single-centre cohort study', European heart journal-Cardiovascular pharmacotherapy, vol. 9, no. 7, pp. 617-626. https://doi.org/10.1093/ehjcvp/pvad048

Subject Terms: Platelet Aggregation Inhibitors/adverse effects, Ticagrelor, ST Elevation Myocardial Infarction/diagnosis, ST-segment elevation myocardial infarction (STEMI), Hemorrhage, Prasugrel Hydrochloride/adverse effects, Clopidogrel/adverse effects, 3. Good health, Clopidogrel, Cohort Studies, Ticagrelor/adverse effects, Percutaneous Coronary Intervention, Hemorrhage/chemically induced, Humans, ST Elevation Myocardial Infarction, Female, High bleeding risk, percutaneous coronary intervention (PCI), P2Y12 inhibitors, Dual antiplatelet therapy (DAPT), Prasugrel Hydrochloride, Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention/adverse effects, predicting bleeding complications in patients undergoing stent implantation and subsequent DAPT (PRECISE-DAPT), Aged

Access URL: https://pubmed.ncbi.nlm.nih.gov/37403404
https://vbn.aau.dk/da/publications/803afeec-ae09-483e-886b-1fc8fd076d03
https://doi.org/10.1093/ehjcvp/pvad048
http://www.scopus.com/inward/record.url?scp=85177482584&partnerID=8YFLogxK
https://pure.au.dk/portal/en/publications/cf5f699a-9086-408c-a2a2-30d6d33b272a
https://doi.org/10.1093/ehjcvp/pvad048

Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: Full results of the PERSEUS randomized trial

Authors: Iglesias J. F. Valgimigli M. Carbone F. et al.

Source: Cardiol J
Cardiology journal, vol. 29, no. 4, pp. 591-600

Subject Terms: Ticagrelor, Morphine, Platelet Function Tests, fentanyl, pharmacodynamics, pharmacokinetics, ST-segment elevation myocardial infarction, ticagrelor, Clinical Cardiology, 3. Good health, Fentanyl, 03 medical and health sciences, Percutaneous Coronary Intervention, Treatment Outcome, 0302 clinical medicine, Purinergic P2Y Receptor Antagonists, Humans, ST Elevation Myocardial Infarction, Fentanyl/adverse effects, Percutaneous Coronary Intervention/adverse effects, Platelet Aggregation Inhibitors, Prospective Studies, ST Elevation Myocardial Infarction/diagnosis, ST Elevation Myocardial Infarction/drug therapy, Ticagrelor/adverse effects

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/35762079
https://serval.unil.ch/resource/serval:BIB_EA3BAC8B3284.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_EA3BAC8B3284
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_EA3BAC8B32848
https://hdl.handle.net/11567/1162862
https://doi.org/10.5603/CJ.a2022.0049

Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis

Authors: Orban, Martin Kleeberger, Jan Ouarrak, Taoufik et al.

Contributors: Orban, Martin Kleeberger, Jan Ouarrak, Taoufik et al.

Source: Clin Res Cardiol

Subject Terms: Male, Ticagrelor, Myocardial Infarction, Shock, Cardiogenic, Hemorrhage, shock, ticagrelor, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, cardiogenic, Humans, Prospective Studies, 10. No inequality, Cardiogenic shock, Aged, antagonists, Aged, 80 and over, 2. Zero hunger, clopidogrel, Original Paper, Intra-Aortic Balloon Pumping, Bleeding, Aged, 80 and over [MeSH], Aged [MeSH], Prasugrel Hydrochloride/adverse effects [MeSH], Clopidogrel, Prasugrel Hydrochloride/administration, Platelet Aggregation Inhibitors/administration, Shock, Cardiogenic/therapy [MeSH], Percutaneous Coronary Intervention [MeSH], Male [MeSH], Myocardial Infarction/complications [MeSH], Shock, Cardiogenic/mortality [MeSH], Myocardial Infarction/therapy [MeSH], Female [MeSH], Myocardial Infarction/mortality [MeSH], Follow-Up Studies [MeSH], Hemorrhage/chemically induced [MeSH], Humans [MeSH], Prasugrel, Prospective Studies [MeSH], Ticagrelor/administration, Clopidogrel/adverse effects [MeSH], Clopidogrel/administration, Ticagrelor/adverse effects [MeSH], Intra-Aortic Balloon Pumping/methods [MeSH], Middle Aged [MeSH], ADP-receptor antagonists, Platelet Aggregation Inhibitors/adverse effects [MeSH], Middle Aged, bleeding, prasugrel, 3. Good health, [SDV] Life Sciences [q-bio], ADP-receptor, Female, Prasugrel Hydrochloride, Platelet Aggregation Inhibitors, Follow-Up Studies

File Description: application/pdf

Access URL: https://link.springer.com/content/pdf/10.1007/s00392-021-01866-3.pdf
https://pubmed.ncbi.nlm.nih.gov/33999281
https://www.ncbi.nlm.nih.gov/pubmed/33999281
https://europepmc.org/article/MED/33999281
https://link.springer.com/article/10.1007/s00392-021-01866-3
https://ruj.uj.edu.pl/xmlui/handle/item/278798
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405498
https://pubmed.ncbi.nlm.nih.gov/33999281/
https://link.springer.com/article/10.1007/s00392-021-01866-3
https://doi.org/10.1007/s00392-021-01866-3
https://link.springer.com/article/10.1007/s00392-021-01866-3
https://ruj.uj.edu.pl/xmlui/handle/item/278798
https://repository.publisso.de/resource/frl:6447523
https://hal.sorbonne-universite.fr/hal-03242664v1/document
https://doi.org/10.1007/s00392-021-01866-3
https://hal.sorbonne-universite.fr/hal-03242664v1
https://epub.ub.uni-muenchen.de/76482/

Sex-Specific Differences in Potent P2Y 12 Inhibitor Use in British Cardiovascular Intervention Society Registry STEMI Patients

Authors: Sonya N. Burgess Ahmad Shoaib Andrew S.P. Sharp et al.

Source: Burgess, S, Shoaib, A, Sharp, A, Ludman, P, Graham, M M, Figtree, G A, Kontopantelis, E, Rashid, M & Kinnaird, T 2023, 'Sex-specific differences in potent P2Y12 inhibitor use in British Cardiovascular Intervention Society registry STEMI patients', Circulation: Cardiovascular Interventions, vol. 16, no. 9, e012447. https://doi.org/10.1161/CIRCINTERVENTIONS.122.012447

Subject Terms: Male, Ticagrelor, ST Elevation Myocardial Infarction/diagnosis, Prasugrel Hydrochloride/adverse effects, 3. Good health, Clopidogrel, Ticagrelor/adverse effects, 03 medical and health sciences, 0302 clinical medicine, Treatment Outcome, Humans, ST Elevation Myocardial Infarction, Female, Registries, Prasugrel Hydrochloride

File Description: application/vnd.openxmlformats-officedocument.wordprocessingml.document

Access URL: https://pubmed.ncbi.nlm.nih.gov/37725676
https://research.manchester.ac.uk/en/publications/68d56564-fa92-4db0-94a7-ba144ee1d9f4
https://doi.org/10.1161/CIRCINTERVENTIONS.122.012447
https://pure.manchester.ac.uk/ws/files/270578305/TRACKED_P2Y12_july14_MAM_SB.docx
https://research.manchester.ac.uk/en/publications/68d56564-fa92-4db0-94a7-ba144ee1d9f4
https://doi.org/10.1161/CIRCINTERVENTIONS.122.012447

Sex Differences in Outcomes of Ticagrelor Therapy With or Without Aspirin After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Secondary Analysis of the TICO Randomized Clinical Trial

Authors: Bom Lee Seung-Jun Lee Byeong-Keuk Kim et al.

Contributors: Bom Lee Seung-Jun Lee Byeong-Keuk Kim et al.

Source: Arteriosclerosis, Thrombosis, and Vascular Biology. 43

Subject Terms: drug, Male, Ticagrelor, Aspirin / adverse effects, Ticagrelor / adverse effects, Hemorrhage, ticagrelor, Percutaneous Coronary Intervention, sex, Humans, Acute Coronary Syndrome, 10. No inequality, thrombosis, Sex Characteristics, Aspirin, Platelet Aggregation Inhibitors / adverse effects, Drug-Eluting Stents, 3. Good health, Percutaneous Coronary Intervention* / adverse effects, eluting stents, incidence, Drug-Eluting Stents* / adverse effects, Female, Acute Coronary Syndrome* / drug therapy, Hemorrhage / epidemiology, Platelet Aggregation Inhibitors

Access URL: https://pubmed.ncbi.nlm.nih.gov/37021576

Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial: the randomised, open-label, non-inferiority trial

Authors: Gimbel M. Qaderdan K. Willemsen L. et al.

Contributors: Gimbel M. Qaderdan K. Willemsen L. et al.

Source: The Lancet. 395:1374-1381

Subject Terms: Male, Platelet Aggregation Inhibitors/adverse effects, Ticagrelor, Myocardial Infarction, Clopidogrel/adverse effects, 03 medical and health sciences, Acute Coronary Syndrome/drug therapy, 0302 clinical medicine, Taverne, Journal Article, 80 and over, Humans, Acute Coronary Syndrome, Stroke/prevention & control, Aged, Aged, 80 and over, Research Support, Non-U.S. Gov't, General Medicine, Prasugrel Hydrochloride/adverse effects, Clopidogrel, 3. Good health, Stroke, Ticagrelor/adverse effects, Myocardial Infarction/prevention & control, Female, Prasugrel Hydrochloride, Platelet Aggregation Inhibitors

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/32334703
https://research-portal.uu.nl/en/publications/56ee5aea-ea09-4c92-a769-8c522430317e
https://doi.org/10.1016/S0140-6736(20)30325-1
https://www.ncbi.nlm.nih.gov/pubmed/32334703
https://www.narcis.nl/publication/RecordID/oai%3Ascholarlypublications.universiteitleiden.nl%3Aitem_3232707
https://research.utwente.nl/en/publications/clopidogrel-versus-ticagrelor-or-prasugrel-in-patients-aged-70-ye
https://www.sciencedirect.com/science/article/pii/S0140673620303251
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30325-1/fulltext
https://utwente-staging.elsevierpure.com/en/publications/clopidogrel-versus-ticagrelor-or-prasugrel-in-patients-aged-70-ye
https://dspace.library.uu.nl/handle/1874/439683
https://hdl.handle.net/1887/3232707
https://dspace.library.uu.nl/handle/1874/408889

A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI

Authors: Johannes C. Kelder Carmine Morisco Jean-Paul R. Herrman et al.

Contributors: Johannes C. Kelder Carmine Morisco Jean-Paul R. Herrman et al.

Source: New England Journal of Medicine. 381:1621-1631

Subject Terms: Male, Ticagrelor, Genotype, ST Elevation Myocardial Infarction/drug therapy, PERCUTANEOUS CORONARY INTERVENTION, MULTICENTER, Administration, Oral, Hemorrhage, Clopidogrel/adverse effects, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, Hemorrhage/chemically induced, Taverne, STENT THROMBOSIS, Journal Article, Humans, ST-SEGMENT ELEVATION, Single-Blind Method, Precision Medicine, Aged, Medicine(all), OUTCOMES, Research Support, Non-U.S. Gov't, Coronary Thrombosis, ELEVATION MYOCARDIAL-INFARCTION, DUAL ANTIPLATELET THERAPY, General Medicine, Middle Aged, Prasugrel Hydrochloride/adverse effects, OPEN-LABEL, Clopidogrel, Intention to Treat Analysis, 3. Good health, Coronary Thrombosis/prevention & control, Multicenter Study, Cytochrome P-450 CYP2C19, PCI, P2Y12, Ticagrelor/adverse effects, CYP2C19 GENOTYPE, CLOPIDOGREL, Purinergic P2Y Receptor Antagonists/adverse effects, Randomized Controlled Trial, Purinergic P2Y Receptor Antagonists, ST Elevation Myocardial Infarction, Female, Stents, Cytochrome P-450 CYP2C19/genetics, Prasugrel Hydrochloride

File Description: application/pdf; image/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/31479209
http://hdl.handle.net/11588/758723
https://hdl.handle.net/11370/650391a9-784b-433f-a595-a7bf8062502a
https://doi.org/10.1056/NEJMoa1907096
https://research.rug.nl/en/publications/650391a9-784b-433f-a595-a7bf8062502a
https://cris.maastrichtuniversity.nl/en/publications/bb73e8c6-3735-412e-9308-2d05f5549d34
https://doi.org/10.1056/NEJMoa1907096
https://pubmed.ncbi.nlm.nih.gov/31479209/
https://europepmc.org/article/MED/31479209
https://www.rug.nl/research/portal/publications/a-genotypeguided-strategy-for-oral-p2y12-inhibitors-in-primary-pci(650391a9-784b-433f-a595-a7bf8062502a).html
https://www.ncbi.nlm.nih.gov/pubmed/31479209/
https://www.narcis.nl/publication/RecordID/oai%3Acris.maastrichtuniversity.nl%3Apublications%2Fbb73e8c6-3735-412e-9308-2d05f5549d34
https://research.rug.nl/en/publications/a-genotype-guided-strategy-for-oral-p2y12-inhibitors-in-primary-p
https://dspace.library.uu.nl/handle/1874/453165
https://dspace.library.uu.nl/handle/1874/389963
https://dspace.library.uu.nl/handle/1874/390371

Ticagrelor in Patients with Stable Coronary Disease and Diabetes

Authors: Steg, Philippe Gabriel Bhatt, Deepak Simon, Tabassome et al.

Contributors: Steg, Philippe Gabriel Bhatt, Deepak Simon, Tabassome et al.

Source: The New England Journal of Medicine, 381, 14, pp. 1309-1320
The New England journal of medicine, Vol. 381, no. 14, p. 1309-1320 (2019)
Steg, P G, Bhatt, D L, Simon, T, Fox, K, Mehta, S R, Harrington, R A, Held, C, Andersson, M, Himmelmann, A, Ridderstråle, W, Leonsson-Zachrisson, M, Liu, Y, Opolski, G, Zateyshchikov, D, Ge, J, Nicolau, J C, Corbalán, R, Cornel, J H, Widimský, P, Leiter, L A & THEMIS Steering Committee and Investigators 2019, 'Ticagrelor in Patients with Stable Coronary Disease and Diabetes', The New England Journal of Medicine, vol. 381, no. 14, pp. 1309-1320. https://doi.org/10.1056/NEJMoa1908077

Subject Terms: Male, Ticagrelor, THEMIS Steering Committee and Investigators, CLINICAL BENEFIT, Myocardial Infarction, Coronary Artery Disease, Kaplan-Meier Estimate, SECONDARY PREVENTION, Stroke/epidemiology, 0302 clinical medicine, Hemorrhage/chemically induced, PRASUGREL, Cardiology - Radboud University Medical Center, 11 Medical and Health Sciences, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Incidence, DUAL ANTIPLATELET THERAPY, 60 MG, Middle Aged, 3. Good health, Drug Therapy, Combination/adverse effects, Stroke, Ticagrelor/adverse effects, Treatment Outcome, CLOPIDOGREL, Combination, Medicine, PLATELET INHIBITION, Drug Therapy, Combination, Female, Aged, Aspirin, Diabetes Mellitus, Type 2, Double-Blind Method, Follow-Up Studies, Hemorrhage, Humans, Platelet Aggregation Inhibitors, Radboudumc 6: Metabolic Disorders RIMLS: Radboud Institute for Molecular Life Sciences, Life Sciences & Biomedicine, Type 2, Coronary Artery Disease/complications, Platelet Aggregation Inhibitors/adverse effects, General & Internal, Aspirin/adverse effects, 03 medical and health sciences, Radboudumc 16: Vascular damage RIHS: Radboud Institute for Health Sciences, Medicine, General & Internal, Drug Therapy, General & Internal Medicine, Diabetes Mellitus, Myocardial Infarction/epidemiology, Internal Medicine - Radboud University Medical Center, CARDIOVASCULAR EVENTS, Science & Technology, Diabetes Mellitus, Type 2/complications, MYOCARDIAL-INFARCTION, COLLABORATIVE METAANALYSIS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology

File Description: application/pdf; 12 páginas

Access URL: https://pubmed.ncbi.nlm.nih.gov/31475798
https://pubmed.ncbi.nlm.nih.gov/31475798/
https://www.narcis.nl/publication/RecordID/oai%3Arepository.ubn.ru.nl%3A2066%2F208849
http://www.diva-portal.org/smash/record.jsf?pid=diva2:1365374
https://www.nejm.org/doi/full/10.1056/NEJMoa1908077
https://www.nejm.org/doi/suppl/10.1056/NEJMoa1908077/suppl_file/nejmoa1908077_appendix.pdf
https://www.ncbi.nlm.nih.gov/pubmed/31475798
http://hdl.handle.net/10044/1/73277
https://hdl.handle.net/2066/208849
https://hdl.handle.net/2078.1/235243
https://hal.umontpellier.fr/hal-02859897v1
https://doi.org/10.1056/nejmoa1908077

One-year clinical outcomes of ticagrelor compared with clopidogrel after percutaneous coronary intervention in patients with acute myocardial infarction: From Korean Health Insurance Review and Assessment Data

Authors: Choongki Kim Dong-Ho Shin Sung-Jin Hong et al.

Contributors: Choongki Kim Dong-Ho Shin Sung-Jin Hong et al.

Source: Journal of Cardiology. 73:191-197

Subject Terms: Male, Ticagrelor, Clopidogrel / administration & dosage, Myocardial Infarction, Ticagrelor / adverse effects, Hemorrhage, Platelet Aggregation Inhibitors / administration & dosage, Coronary artery disease, Insurance, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, Ticagrelor / administration & dosage, Cause of Death, Republic of Korea, Odds Ratio, Humans, Republic of Korea / epidemiology, Aged, Insurance, Health, Stroke / etiology, Drug Substitution, Incidence, Stroke / epidemiology, Clopidogrel / adverse effects, Platelet Aggregation Inhibitors / adverse effects, Platelet inhibitors, Middle Aged, Combined Modality Therapy, Myocardial Infarction / mortality, Clopidogrel, 3. Good health, Treatment, Stroke, Myocardial infarction, Treatment Outcome, Health, Hemorrhage / chemically induced, Myocardial Infarction / complications, Female, Myocardial Infarction / therapy, Platelet Aggregation Inhibitors

Access URL: http://www.journal-of-cardiology.com/article/S0914508718302648/pdf
https://pubmed.ncbi.nlm.nih.gov/30770037
https://yonsei.pure.elsevier.com/en/publications/one-year-clinical-outcomes-of-ticagrelor-compared-with-clopidogre
https://pubmed.ncbi.nlm.nih.gov/30770037/
https://www.ncbi.nlm.nih.gov/pubmed/30770037
https://www.sciencedirect.com/science/article/pii/S0914508718302648

Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine: ATLANTIC-Morphine

Authors: Lapostolle, Frederic van't Hof, Arnoud W. Hamm, Christian W. et al.

Contributors: Lapostolle, Frederic van't Hof, Arnoud W. Hamm, Christian W. et al.

Source: Lapostolle, F, Van't Hof, A W, Hamm, C W, Stibbe, O, Ecollan, P, Collet, J-P, Silvain, J, Lassen, J F, Heutz, W M J M, Bolognese, L, Cantor, W J, Cequier, A, Chettibi, M, Goodman, S G, Hammett, C J, Huber, K, Janzon, M, Merkely, B, Storey, R F, Ten Berg, J, Zeymer, U, Licour, M, Tsatsaris, A, Montalescot, G, Jensen, L O, Köhler, D & ATLANTIC Investigators 2019, ' Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction : ATLANTIC-Morphine ', American Journal of Cardiovascular Drugs, vol. 19, no. 2, pp. 173–183 . https://doi.org/10.1007/s40256-018-0305-0
Lapostolle, F, van’t Hof, A W, Hamm, C W, Stibbe, O, Ecollan, P, Collet, J P, Silvain, J, Lassen, J F, Heutz, W M J M, Bolognese, L, Cantor, W J, Cequier, A, Chettibi, M, Goodman, S G, Hammett, C J, Huber, K, Janzon, M, Merkely, B, Storey, R F, ten Berg, J, Zeymer, U, Licour, M, Tsatsaris, A, Montalescot, G & for the ATLANTIC Investigators 2019, 'Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction : ATLANTIC-Morphine', American Journal of Cardiovascular Drugs, vol. 19, no. 2, pp. 173-183. https://doi.org/10.1007/s40256-018-0305-0

Subject Terms: Adult, Male, Platelet Aggregation Inhibitors/adverse effects, Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors, Ticagrelor, Cardiac & Cardiovascular Systems, [SDV]Life Sciences [q-bio], Pain, Platelet Glycoprotein GPIIb-IIIa Complex, Cardiovascular medicine and haematology, DOUBLE-BLIND, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, PRASUGREL, REPERFUSION, Humans, Pharmacology & Pharmacy, Aged, Retrospective Studies, OUTCOMES, Science & Technology, Morphine, Analgesics, Opioid/adverse effects, ASSOCIATION, Middle Aged, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 3. Good health, [SDV] Life Sciences [q-bio], Analgesics, Opioid, Ticagrelor/adverse effects, INSIGHTS, Treatment Outcome, Pain/complications, Cardiovascular System & Cardiology, ST Elevation Myocardial Infarction, Morphine/adverse effects, TRIAL, Female, Life Sciences & Biomedicine, Platelet Aggregation Inhibitors, ST Elevation Myocardial Infarction/complications

Access URL: https://pubmed.ncbi.nlm.nih.gov/30353444
https://cris.maastrichtuniversity.nl/en/publications/62a8b3df-6e33-42f0-b7ee-d7381bd31b90
https://doi.org/10.1007/s40256-018-0305-0
http://findresearcher.sdu.dk/portal/da/publications/morphine-and-ticagrelor-interaction-in-primary-percutaneous-coronary-intervention-in-stsegment-elevation-myocardial-infarction(edd710db-828c-4020-aedf-27fb29a26ad6).html
https://portal.findresearcher.sdu.dk/en/publications/morphine-and-ticagrelor-interaction-in-primary-percutaneous-coron
https://www.infona.pl/resource/bwmeta1.element.springer-doi-10_1007-S40256-018-0305-0
http://www.diva-portal.org/smash/record.jsf?pid=diva2:1279075
https://www.narcis.nl/publication/RecordID/oai%3Acris.maastrichtuniversity.nl%3Apublications%2F62a8b3df-6e33-42f0-b7ee-d7381bd31b90
https://link.springer.com/article/10.1007/s40256-018-0305-0
https://portal.findresearcher.sdu.dk/da/publications/edd710db-828c-4020-aedf-27fb29a26ad6
https://portal.findresearcher.sdu.dk/da/publications/edd710db-828c-4020-aedf-27fb29a26ad6
https://doi.org/10.1007/s40256-018-0305-0
https://hal.sorbonne-universite.fr/hal-02152619v1
https://doi.org/10.1007/s40256-018-0305-0
http://www.scopus.com/inward/record.url?scp=85055689783&partnerID=8YFLogxK
https://pure.au.dk/portal/en/publications/de6e469d-a3f4-4325-82bf-c13e2edc3bf1
https://doi.org/10.1007/s40256-018-0305-0

Factors Related to Major Bleeding After Ticagrelor Therapy: Results from the TICO Trial

Authors: Jae Young Cho Seung‐Yul Lee Kyeong Ho Yun et al.

Contributors: Jae Young Cho Seung‐Yul Lee Kyeong Ho Yun et al.

Source: J Am Heart Assoc
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 7 (2021)

Subject Terms: Male, Ticagrelor, Time Factors, Ticagrelor / adverse effects, Postoperative Hemorrhage, antiplatelet therapy, acute coronary syndrome, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, Risk Factors, drug‐eluting stent, Republic of Korea, Sirolimus / pharmacology, Diseases of the circulatory (Cardiovascular) system, Humans, Acute Coronary Syndrome, Republic of Korea / epidemiology, Original Research, Aged, Sirolimus, Drug-Eluting Stents, Percutaneous Coronary Intervention / adverse effects, Incidence, Ticagrelor / administration & dosage, Middle Aged, 3. Good health, Acute Coronary Syndrome / therapy, Postoperative Hemorrhage / chemically induced, RC666-701, Postoperative Hemorrhage / epidemiology, Female, Follow-Up Studies

File Description: application/pdf

Access URL: https://www.ahajournals.org/doi/pdf/10.1161/JAHA.120.019630
https://pubmed.ncbi.nlm.nih.gov/33739127
https://doaj.org/article/17714e6a17a64363966b9acca7c2a73c
https://www.ahajournals.org/doi/10.1161/JAHA.120.019630
https://europepmc.org/article/MED/33739127
https://pubmed.ncbi.nlm.nih.gov/33739127/
https://www.ncbi.nlm.nih.gov/pubmed/33739127
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174385

Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis

Authors: Thomas O. Bergmeijer Arnoud W J van 't Hof Emanuele Barbato et al.

Contributors: Thomas O. Bergmeijer Arnoud W J van 't Hof Emanuele Barbato et al.

Source: Circulation: Cardiovascular Interventions. 14

Subject Terms: Platelet Aggregation Inhibitors/adverse effects, Ticagrelor, Genotype, IMPACT, VARIANT, GUIDELINES, CARDIOVASCULAR OUTCOMES, THERAPY, Clopidogrel/adverse effects, acute coronary syndrome, genetic testing, ticagrelor, 03 medical and health sciences, Acute Coronary Syndrome/drug therapy, Percutaneous Coronary Intervention, 0302 clinical medicine, ANTIPLATELET TREATMENT, Taverne, Journal Article, ARTERY-DISEASE, Humans, Acute Coronary Syndrome, POLYMORPHISMS, Percutaneous Coronary Intervention/adverse effects, pharmacogenetics, clopidogrel, Research Support, Non-U.S. Gov't, percutaneous coronary intervention, myocardial infarction, ASSOCIATION, CYP2C19-ASTERISK-17, Prasugrel Hydrochloride/adverse effects, Clopidogrel, 3. Good health, Cytochrome P-450 CYP2C19, Ticagrelor/adverse effects, THROMBOSIS, Treatment Outcome, MYOCARDIAL-INFARCTION, Cytochrome P-450 CYP2C19/genetics, Cardiology and Cardiovascular Medicine, Prasugrel Hydrochloride, Platelet Aggregation Inhibitors, TASK-FORCE

File Description: application/pdf

Access URL: https://www.ahajournals.org/doi/pdf/10.1161/CIRCINTERVENTIONS.120.009434
https://pubmed.ncbi.nlm.nih.gov/33722066
http://hdl.handle.net/11588/855629
https://cris.maastrichtuniversity.nl/en/publications/ec81e862-ff97-4b95-96ae-e2b6ca002799
https://doi.org/10.1161/circinterventions.120.009434
https://www.ahajournals.org/doi/10.1161/CIRCINTERVENTIONS.120.009434
https://europepmc.org/article/MED/33722066
https://cris.maastrichtuniversity.nl/en/publications/clopidogrel-versus-ticagrelor-or-prasugrel-after-primary-percutan
https://www.ncbi.nlm.nih.gov/pubmed/33722066
https://research.rug.nl/en/publications/clopidogrel-versus-ticagrelor-or-prasugrel-after-primary-percutan
https://www.narcis.nl/publication/RecordID/oai%3Apure.rug.nl%3Apublications%2Fc88d7bed-0522-46be-abfa-3331f07b3fe4
https://dspace.library.uu.nl/handle/1874/444852
https://hdl.handle.net/11588/855629
https://doi.org/10.1161/CIRCINTERVENTIONS.120.009434
https://dspace.library.uu.nl/handle/1874/416038

Gut Microbiota‐Dependent Trimethylamine N‐oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS‐TIMI 54 Trial

Authors: Stanley L. Hazen David A. Morrow Zeneng Wang et al.

Source: J Am Heart Assoc
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 10 (2020)

Subject Terms: Male, Ticagrelor, Time Factors, Myocardial Infarction, Ticagrelor / adverse effects, Aspirin / therapeutic use, antiplatelet therapy, Recurrence, Risk Factors, Myocardial Infarction / microbiology, Secondary Prevention, Methylamines / blood, Original Research, Randomized Controlled Trials as Topic, 2. Zero hunger, Trimethylamine N‐oxide, Dual Anti-Platelet Therapy, Middle Aged, Stroke / mortality, stroke, Myocardial Infarction / mortality, Thrombosis / blood, Up-Regulation, 3. Good health, Intestines, Stroke, Treatment Outcome, myocardial infarction, Intestines / microbiology, Female, Dual Anti-Platelet Therapy / adverse effects, Stroke / prevention & control, Gut microbiota, Risk Assessment, Ticagrelor / therapeutic use, ticagrelor, Thrombosis / mortality, Methylamines, Diseases of the circulatory (Cardiovascular) system, Humans, Myocardial Infarction / blood, Aged, gut microbiota, Aspirin, Bacteria, Antiplatelet therapy, Thrombosis / prevention & control, Stroke / blood, Platelet Aggregation Inhibitors / adverse effects, Platelet Aggregation Inhibitors / therapeutic use, cardiovascular death, Myocardial Infarction / drug therapy, United States, Gastrointestinal Microbiome, Myocardial infarction, Bacteria / metabolism, RC666-701, Case-Control Studies, Cardiovascular death, Platelet Aggregation Inhibitors

File Description: application/pdf

Access URL: https://www.ahajournals.org/doi/pdf/10.1161/JAHA.119.015331
https://pubmed.ncbi.nlm.nih.gov/32366163
https://eprints.whiterose.ac.uk/161514/1/JAHA.119.015331.pdf
https://doaj.org/article/257a96ac3be84083853f101c655a058b
https://www.ahajournals.org/doi/epub/10.1161/JAHA.119.015331
https://www.ahajournals.org/doi/10.1161/JAHA.119.015331
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7660879
https://eprints.whiterose.ac.uk/161514/
https://pubmed.ncbi.nlm.nih.gov/32366163/
https://archive-ouverte.unige.ch/unige:163134
https://doi.org/10.1161/jaha.119.015331

Diffuse alveolar hemorrhage associated with ticagrelor therapy after percutaneous coronary intervention

Authors: Yılmaz, Samet Kılıç, Oğuz Yaylalı, Yalın Tolga

Source: Anatol J Cardiol

Subject Terms: Lung Diseases, Male, lung disease, Ticagrelor, loading drug dose, Case Report, oxygen therapy, amlodipine, heparin, anterior myocardial infarction, computer assisted tomography, Postoperative Complications, 0302 clinical medicine, Chest Pain/etiology, Diagnosis, Differential, Hemorrhage/chemically induced/*diagnosis/diagnostic imaging, Humans, Lung Diseases/chemically induced/*diagnosis/diagnostic imaging, Middle Aged, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors/*adverse effects, Postoperative Complications/chemically induced/diagnosis/diagnostic imaging, ST Elevation Myocardial Infarction/complications/diagnostic imaging/therapy, Ticagrelor/*adverse effects, Tomography, X-Ray Computed, Diagnosis, middle aged, differential diagnosis, coronary artery occlusion, postoperative complication, thrombocyte aggregation, thorax radiography, clinical article, adult, ST segment elevation, antithrombocytic agent, drug substitution, drug withdrawal, chemically induced, revascularization, Acute coronary syndrome, Alveolar hemorrhage, Chest Pain, diagnostic imaging, electrocardiography, Kalp ve Kalp Damar Sistemi, complication, Hemorrhage, Article, ticagrelor, hemoptysis, 03 medical and health sciences, male, x-ray computed tomography, case report, human, clopidogrel, ST segment elevation myocardial infarction, percutaneous coronary intervention, ST segment depression, thorax pain, acetylsalicylic acid, bleeding, lung hemorrhage, Differential, ST Elevation Myocardial Infarction, coronary angiography, Platelet Aggregation Inhibitors

File Description: application/pdf

Access URL: https://pubmed.ncbi.nlm.nih.gov/29952365
https://www.anatoljcardiol.com/jvi.aspx?un=AJC-47776
http://www.ncbi.nlm.nih.gov/pubmed/29952365
https://app.trdizin.gov.tr/makale/TWpnNU9EZzJOZz09/diffuse-alveolar-hemorrhage-associated-with-ticagrelor-therapy-after-percutaneous-coronary-intervention
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237799
http://europepmc.org/articles/PMC6237799
https://hdl.handle.net/11499/10719
https://doi.org/10.14744/anatoljcardiol.2018.47776
https://hdl.handle.net/11499/44042
https://doi.org/10.14744/anatoljcardiol.2018.47776
http://acikerisim.pau.edu.tr:8080/xmlui/handle/11499/10719

Clopidogrel Versus Ticagrelor or Prasugrel after Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype: A POPular Genetics Subanalysis

Authors: Claassens, Daniel M.F. Bergmeijer, Thomas O. Vos, Gerrit J.A. et al.

Contributors: Claassens, Daniel M.F. Bergmeijer, Thomas O. Vos, Gerrit J.A. et al.

Subject Terms: acute coronary syndrome, clopidogrel, genetic testing, myocardial infarction, percutaneous coronary intervention, pharmacogenetics, ticagrelor, Percutaneous Coronary Intervention/adverse effects, Humans, Genotype, Ticagrelor/adverse effects, Treatment Outcome, Acute Coronary Syndrome/drug therapy, Clopidogrel/adverse effects, Platelet Aggregation Inhibitors/adverse effects, Prasugrel Hydrochloride/adverse effects, Cytochrome P-450 CYP2C19/genetics, Cardiology and Cardiovascular Medicine, Research Support, Non-U.S. Gov't, Journal Article

File Description: application/pdf

Relation: https://dspace.library.uu.nl/handle/1874/444852

Availability: https://dspace.library.uu.nl/handle/1874/444852

A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI

Authors: Claassens, Daniel M.F. Vos, Gerrit J.A. Bergmeijer, Thomas O. et al.

Contributors: Claassens, Daniel M.F. Vos, Gerrit J.A. Bergmeijer, Thomas O. et al.

Subject Terms: Administration, Oral, Aged, Clopidogrel/adverse effects, Coronary Thrombosis/prevention & control, Cytochrome P-450 CYP2C19/genetics, Female, Genotype, Hemorrhage/chemically induced, Humans, Intention to Treat Analysis, Male, Middle Aged, Percutaneous Coronary Intervention, Prasugrel Hydrochloride/adverse effects, Precision Medicine, Purinergic P2Y Receptor Antagonists/adverse effects, ST Elevation Myocardial Infarction/drug therapy, Single-Blind Method, Stents, Ticagrelor/adverse effects, General Medicine, Research Support, Non-U.S. Gov't, Randomized Controlled Trial, Multicenter Study, Journal Article

File Description: application/pdf

Relation: https://dspace.library.uu.nl/handle/1874/453165

Availability: https://dspace.library.uu.nl/handle/1874/453165

Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial

Authors: Gimbel, Marieke Qaderdan, Khalid Willemsen, Laura et al.

Source: The Lancet HIV vol.395 (2020) date: 2020-04-24 nr.10233 p.1374-1381 [ISSN 0140-6736]

Index Terms: Acute Coronary Syndrome/drug therapy, Aged, Aged, 80 and over, Clopidogrel/adverse effects, Female, Humans, Male, Myocardial Infarction/prevention & control, Platelet Aggregation Inhibitors/adverse effects, Prasugrel Hydrochloride/adverse effects, Stroke/prevention & control, Ticagrelor/adverse effects, Article

URL: https://research-portal.uu.nl/en/publications/56ee5aea-ea09-4c92-a769-8c522430317e
https://dspace.library.uu.nl/bitstream/handle/1874/408889/1_s2.0_S0140673620303251_main.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/408889/1_s2.0_S0140673620303251_main.pdf?sequence=1

Sinoatrial Arrest Caused by Ticagrelor after Angioplasty in a 62-Year-Old Woman with Acute Coronary Syndrome.

Authors: Ye F Silverstein BV Jansen M et al.

Source: Texas Heart Institute journal [Tex Heart Inst J] 2019 Jun 01; Vol. 46 (3), pp. 203-206. Date of Electronic Publication: 2019 Jun 01 (Print Publication: 2019).

Publication Type: Case Reports; Journal Article

Journal Info: Publisher: published in the Cardiovascular Surgical Research Laboratories, Texas Heart Institute Country of Publication: United States NLM ID: 8214622 Publication Model: eCollection Cited Medium: Internet ISSN: 1526-6702 (Electronic) Linking ISSN: 07302347 NLM ISO Abbreviation: Tex Heart Inst J Subsets: MEDLINE

MeSH Terms: Postoperative Complications*, Acute Coronary Syndrome/*surgery , Angioplasty, Balloon, Coronary/*methods , Heart Arrest/*chemically induced , Ticagrelor/*adverse effects, Acute Coronary Syndrome/drug therapy ; Electrocardiography ; Female ; Heart Arrest/diagnosis ; Humans ; Middle Aged ; Purinergic P2Y Receptor Antagonists/adverse effects

Successful Reversal of Bradycardia and Dyspnea With Aminophylline After Ticagrelor Load.

Authors: Minner SA Simone P Chung BB et al.

Source: Journal of pharmacy practice [J Pharm Pract] 2018 Feb; Vol. 31 (1), pp. 112-114. Date of Electronic Publication: 2016 Dec 05.

Publication Type: Case Reports; Journal Article

Journal Info: Publisher: Sage Publications Country of Publication: United States NLM ID: 8900945 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-1937 (Electronic) Linking ISSN: 08971900 NLM ISO Abbreviation: J Pharm Pract Subsets: MEDLINE

MeSH Terms: Adenosine/*analogs & derivatives , Aminophylline/*therapeutic use , Bradycardia/*drug therapy , Dyspnea/*drug therapy, Adenosine/adverse effects ; Aged ; Bradycardia/chemically induced ; Bradycardia/physiopathology ; Dyspnea/chemically induced ; Dyspnea/physiopathology ; Humans ; Male ; Purinergic P1 Receptor Antagonists/therapeutic use ; Purinergic P2Y Receptor Antagonists/adverse effects ; Ticagrelor